After a Decade of Therapy Revolution in Cutaneous Melanoma-Perspectives on Emerging Treatment Strategies

Area of Science:

• Dermatology
• Oncology
• Immunology

Background:

• The therapeutic landscape for cutaneous melanoma has significantly evolved due to breakthroughs in immuno-oncology and precision medicine.
• Established treatments include immune checkpoint blockade and targeted therapies, with ongoing efforts to enhance efficacy and response durability.

Purpose of the Study:

• To review recent clinical trials and advancements in systemic melanoma therapy.
• To summarize emerging treatment strategies, including neoadjuvant therapy, combinatorial immune checkpoint inhibition, and novel cellular approaches.

Main Methods:

• Review of clinical trials and translational research in melanoma treatment.
• Summary of progress in combinatorial immune checkpoint inhibition (e.g., anti-LAG-3, anti-TIGIT with anti-PD-1).
• Overview of next-generation bispecific antibodies, mRNA vaccines, intralesional therapies, and adoptive cell therapy (TILs, engineered T cells).

Main Results:

• Clinical trials support the use of neoadjuvant therapy in melanoma management.
• Combinatorial immune checkpoint inhibition and novel cellular therapies show promise.
• Advancements include bispecific antibodies, mRNA vaccines, and intralesional treatments.

Conclusions:

• Future melanoma management will integrate insights from clinical and translational research.
• Key challenges include optimizing treatment sequencing and advancing biomarker research.
• Promising therapeutic avenues are emerging for systemic melanoma treatment.